Cardiovascular Disease, Heart Failure and Preserved Ejection Fraction

Cardiovascular Disease

Heart Failure

Preserved Ejection Fraction

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Heart failure with preserved ejection fraction (HFpEF) is the largest unmet clinical need in cardiovascular medicine. Despite decades of research, the treatment option for HFpEF is still limited, indicating our ongoing incomplete understanding on the underlying molecular mechanisms.

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Biomarkers Cardiovascular Disease

Extracoronary Calcification Increases Risk of Incident HF, HFpEF

American College of Cardiology

MARCH 26, 2025

Among a cohort of multiethnic participants without baseline cardiovascular disease, the presence of extracoronary calcification (ECC) at baseline was independently associated with an increased risk for heart failure (HF), especially HF with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction

Preserved Ejection Fraction Heart Failure Cardiovascular Disease Article

Hypertensive pregnancy disorder, an under‐recognized women specific risk factor for heart failure?

European Journal of Heart Failure

NOVEMBER 19, 2024

Hypertensive disorders of pregnancy as a risk factor for heart failure. BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; HELLP, haemolysis, elevated liver enzymes, low platelet count.

Risk Factors

Risk Factors Heart Failure Hypertension Preserved Ejection Fraction

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24

DAIC

APRIL 3, 2024

Cardiovascular Update for the Clinician: A Symposium by Valentin Fuster” will offer the latest advances in the treatment of cardiovascular disease and ways to integrate them into daily practice. 24 Education Sessions Symposiums at ACC The “Symposiums at ACC.24”

Education

Education Preserved Ejection Fraction Coronary Artery Disease Cardio Oncology

Abstract 4141446: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors Promote Resiliency to High Pressure Stress in the Human Microvasculature

Circulation

NOVEMBER 11, 2024

Emerging evidence suggests that vascular stress from cardiovascular-related co-morbidities promotes microvascular dysfunction, a key component in the development of heart failure with preserved ejection fraction.

Preserved Ejection Fraction

Preserved Ejection Fraction Arterioles Heart Failure Risk Factors

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

DAIC

FEBRUARY 29, 2024

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)

Aortic valve

Aortic valve Myocardial Infarction Aortic Blood Pressure

Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity

European Journal of Heart Failure

DECEMBER 13, 2023

Abstract Aim Epicardial adipose tissue (EAT) plays a role in obesity-related heart failure with preserved ejection fraction. However, the association of EAT thickness with the development of cardiac dysfunction in subjects with severe obesity without known cardiovascular disease is unclear.

Obesity

Obesity Preserved Ejection Fraction BMI Heart Failure

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

DAIC

MARCH 26, 2025

Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Heart Failure

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor

Can heart failure phenotypes be predicted by cardiac remodelling peripartum or postpartum?

Frontiers in Cardiovascular Medicine

AUGUST 6, 2024

In the short-term it can result in pre-eclampsia, haemolysis, elevated liver enzymes and low platelets (HELLP) syndrome, or even hypertension associated acute heart failure, all of which may necessitate pre-term delivery to prevent maternal or neonatal death.

Heart Failure

Heart Failure Preserved Ejection Fraction Coronary Artery Disease Hypertension

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity

Obesity BMI Heart Failure Cardiovascular Disease

SBC Scientific Publication Award 2023 Held at the 79th Brazilian Congress of Cardiology

International Journal of Cardiovascular Sciences

OCTOBER 21, 2024

Award Winners: Arquivos Brasileiros de Cardiologia Best Original Article – Determining Percentiles of Atherosclerotic Cardiovascular Risk According to Sex and Age in a Healthy Brazilian Population Authors: Fernando Yue Cesena, Nea Miwa Kashiwagi, Carlos Andre Minanni, Raul D.

Article

Article Preserved Ejection Fraction COVID-19 Heart Failure

Highlights of ACC 2024

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina

Angina Myocardial Infarction Aortic valve Coronary Artery Disease

What Cardiometabolic Clinicians Can Be Thankful For This Year

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).

Blood Pressure

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Moreover, cardiovascular disease in women continues to be underrepresented and undertreated.

CME

CME Obesity Heart Failure Biomarkers

Cardiovascular Update

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction

Extracoronary Calcification Increases Risk of Incident HF, HFpEF

Hypertensive pregnancy disorder, an under‐recognized women specific risk factor for heart failure?

Webinars

American College of Cardiology Sets Full Range of Education Sessions and Meetings ACC Scientific Session, ACC.24

Abstract 4141446: Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors Promote Resiliency to High Pressure Stress in the Human Microvasculature

American College of Cardiology ACC.24 Late-breaking Science and Guidelines Session Summary

Association between epicardial adipose tissue and cardiac dysfunction in subjects with severe obesity

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

Can heart failure phenotypes be predicted by cardiac remodelling peripartum or postpartum?

Expert Perspective: The Obesity Paradox with Salvatore Carbone, PhD

SBC Scientific Publication Award 2023 Held at the 79th Brazilian Congress of Cardiology

Highlights of ACC 2024

What Cardiometabolic Clinicians Can Be Thankful For This Year

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC)

Stay Connected